Search

Your search keyword '"Celma, Ana"' showing total 163 results
Start Over Author "Celma, Ana"
163 results on '"Celma, Ana"'

4. The Role of Digital Rectal Examination for Early Detection of Significant Prostate Cancer in the Era of Magnetic Resonance Imaging.

Author

Morote, Juan, Paesano, Nahuel, Picola, Natàlia, Muñoz-Rodriguez, Jesús, Ruiz-Plazas, Xavier, Muñoz-Rivero, Marta V., Celma, Ana, García-de Manuel, Gemma, Miró, Berta, Abascal, José M., Servian, Pol, Méndez, Olga, and Trilla, Enrique

Abstract

The role of digital rectal examination (DRE) in the early detection of significant prostate cancer (PCa) is being questioned in the era of magnetic resonance imaging (MRI). However, some men with suspected PCa may still be identified solely through DRE, even with low serum prostate-specific antigen (PSA) levels. Additionally, most predictive models designed to improve significant PCa diagnostic pathways incorporate DRE findings. We assessed the role of DRE among 5005 men with serum PSA levels > 3.0 ng/mL and/or suspicious DRE findings, who underwent pre-biopsy MRI and targeted and/or systematic biopsies, as part of the significant PCa opportunistic screening program in Catalonia (Spain) between 2016 and 2023. Significant PCa, defined as grade group > 2, was detected in 2097 men (41.9%). Suspicion of PCa was based solely on DRE in 206 cases (4.1%) with significant PCa detected in 50 of them (2.4%). Two pathways using the Barcelona predictive models, before and after MRI, with and without DRE findings showed specificities of 52.8 and 38.7%, respectively (p < 0.001), after fixing sensitivity at 90%. Prostate biopsy was avoided in 35.1 and 26.7%, respectively (p < 0.001), while its efficacy increased from 52.8 to 58%. We conclude that DRE improved the effectiveness of an opportunistic significant PCa-screening program. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

6. Mapping the Patient-Oriented Prostate Utility Scale From the Expanded Prostate Cancer Index Composite and the Short-Form Health Surveys

Author

Ferrer, Montse, Pont, Àngels, Garin, Olatz, Pardo, Yolanda, Zamora, Víctor, Gutiérrez, Cristina, Ventura, Montse, Guedea, Ferran, Ferrer, Ferran, Boladeras, Ana, Slocker, Andrea, Suárez, José Francisco, Castells, Manuel, Bonet, Xavier, Cabrera, Patricia, Delgado, David B., Ortiz, M<ce:sup loc='post">a</ce:sup>José, Herruzo, Ismael, López-Torrecilla, José, Pastor, Jorge, Muñoz, Víctor, Willsich, Patricia, Vázquez, Marisa, Roselló, Àlvar, Eraso, Arantxa, Ferrer, Carlos, Sánchez, Ángel, Gómez-Veiga, Francisco, Macías, Víctor, Fumadó, Lluís, Jové, Josep, Mira, Moisés, Villafranca, Elena, Morote, Juan, Celma, Ana, Samper, Pilar, Glaría, Luís A., Cabeza, M<ce:sup loc='post">a</ce:sup>Ángeles, Juan, Germán, Méndez Ramírez, Samuel, Palacios, Amalia, Béjar, Amelia, Garcia, Sonia, Sabater, Sebastà, Pijoan, José Ignacio, and Litwin, Mark S.

Published
2021
Full Text
View/download PDF

7. Association of the rs1042522 SNP with prostate cancer risk: a study of cancer tissues, primary tumor cultures, and serum samples from a Spanish Caucasian population.

Author

Toscano-Guerra, Emily, Maggio, Valentina, García, Javier, Semidey, Maria Eugenia, Celma, Ana, Morote, Juan, de Torres, Inés, Giralt, Marina, Ferrer-Costa, Roser, and Paciucci, Rosanna

Subjects
RADICAL prostatectomy, TUMOR suppressor genes, SINGLE nucleotide polymorphisms, PROSTATE cancer, DISEASE risk factors, GLEASON grading system
Abstract

Background: Prostate cancer (PCa) is a leading cause of cancer-related deaths in European men, emphasizing the urgent need for effective risk assessment strategies. The TP53 gene, a tumor suppressor gene frequently mutated in cancer, commonly harbors the rs1042522 single nucleotide polymorphism (SNP), known as the P72R SNP, which may influence PCa susceptibility. This study investigated the prevalence of the P72R SNP in European Caucasian PCa samples and its association with PCa risk. Methods: Genotyping was conducted on 12 hormone-naïve aggressive PCa cultures (hnPCs) from untreated patients (Gleason ≥8), 11 radical prostatectomies (RP), and 94 serum samples using DNA Sanger sequencing and melting curve analysis. Comparative analysis utilized data from the GnomAD database's European Caucasian non-cancer population. Results: Our results demonstrate a significantly higher frequency of the P72R SNP in PCa samples and serums compared to the general European non-cancer population. A robust and statistically significant association (p < 0.0001) between the SNP and prostate cancer risk was identified, with an odds ratio of 7.937 (95% CI 5.37-11.00). Notably, the G allele (R72) showed a pronounced prevalence in high Gleason score (≥8) patients, although statistical significance was not reached. These results highlight a potential association with undifferentiated and malignant PCa lesions. Conclusion: The compelling association between the P72R SNP and prostate cancer risk underscores the potential utility of this marker for the early identification of patients at risk of aggressive metastatic prostate cancer. This insight could empower further research to intervene at an early stage by offering enhanced opportunities for timely and targeted interventions. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

10. Association of the rs1042522 SNP with prostate cancer risk: a study of cancer tissues, primary tumor cultures and serum samples from a European Caucasian population

Author

Toscano-Guerra, Emily, primary, Maggio, Valentina, additional, García, Javier, additional, Semidey, Maria Eugenia, additional, Celma, Ana, additional, Morote, Juan, additional, Torres, Inés de, additional, Giralt, Marina, additional, Ferrer, Roser, additional, and Paciucci, Rosanna, additional

Published
2024
Full Text
View/download PDF

11. The Role of Digital Rectal Examination Prostate Volume Category in the Early Detection of Prostate Cancer: Its Correlation with the Magnetic Resonance Imaging Prostate Volume

Author

Morote, Juan, primary, Picola, Natàlia, additional, Muñoz-Rodriguez, Jesús, additional, Paesano, Nahuel, additional, Ruiz-Plazas, Xavier, additional, Muñoz-Rivero, Marta V., additional, Celma, Ana, additional, García-de Manuel, Gemma, additional, Miró, Berta, additional, Abascal, José M., additional, and Servian, Pol, additional

Published
2024
Full Text
View/download PDF

14. Circulating tumor extracellular vesicles to monitor metastatic prostate cancer genomics and transcriptomic evolution

Author

Casanova-Salas, Irene, Aguilar, Daniel, Cordoba-Terreros, Sarai, Agundez, Laura, Brandariz, Julian, Herranz, Nicolas, Mas, Alba, Gonzalez, Macarena, Morales-Barrera, Rafael, Sierra, Alexandre, Soriano-Navarro, Mario, Cresta, Pablo, Mir, Gisela, Simonetti, Sara, Rodrigues, Gonçalo, Arce-Gallego, Sara, Delgado-Serrano, Luisa, Agustí, Irene, Castellano-Sanz, Elena, Mast, Richard, de Albert, Matias, Celma, Ana, Santamaria, Anna, Gonzalez, Lucila, Castro, Natalia, Suanes, Maria del Mar, Hernández-Losa, Javier, Nonell, Lara, Peinado, Hector, Carles, Joan, and Mateo, Joaquin

Published
2024
Full Text
View/download PDF

16. Circulating tumor extracellular vesicles to monitor metastatic prostate cancer genomics and transcriptomic evolution

Author

Casanova-Salas, Irene, primary, Cordoba-Terreros, Sarai, additional, Aguilar, Daniel, additional, Agundez, Laura, additional, Brandariz, Julian, additional, Herranz, Nicolas, additional, Gonzalez, Macarena, additional, Morales-Barrera, Rafael, additional, Sierra, Alexandre, additional, Soriano-Navarro, Mario, additional, Cresta, Pablo, additional, Simonetti, Sara, additional, Rodrigues, Goncalo, additional, Arce-Gallego, Sara, additional, Delgado, Luisa, additional, Agusti, Irene, additional, Castellano-Sanz, Elena, additional, Mast, Richard, additional, de Albert, Matias, additional, Celma, Ana, additional, Santamaria, Anna, additional, Gonzalez, Lucila, additional, Castro, Natalia, additional, Suanes, Maria del Mar, additional, Hernandez-Losa, Javier, additional, Nonell, Lara, additional, Peinado, Hector, additional, Carles, Joan, additional, and Mateo, Joaquin, additional

Published
2023
Full Text
View/download PDF

19. Multiparametric Magnetic Resonance Imaging Grades the Aggressiveness of Prostate Cancer

Author

Morote Robles, Juan, Borque-Fernando, Angel, Triquell, Marina, Celma, Ana, Regis, Lucas, Mast, Richard, de Torres, Inés, Semidey, María E., Santamaría, Anna, Planas, Jacques, Esteban, Luis M., Trilla Herrera, Enrique, Morote Robles, Juan, Borque-Fernando, Angel, Triquell, Marina, Celma, Ana, Regis, Lucas, Mast, Richard, de Torres, Inés, Semidey, María E., Santamaría, Anna, Planas, Jacques, Esteban, Luis M., and Trilla Herrera, Enrique

Abstract

Prostate cancer (PCa) aggressiveness can be assessed from clinical and pathologic surrogate endpoints as the International Society of Uropathology grade group (GG) in prostate biopsies, the type of pathology from surgical specimens, the clinical stage, and the risk of biochemical recurrence after treatment of localised PCa. Low evidence exists about the association between prostate magnetic resonance imaging (MRI) and PCa aggressiveness beyond the known increased risk of clinically significant PCa (csPCa) as Prostate Imaging and Data Report System (PI-RADS) increase. Therefore, we confirm previous data and generate new evidence from all the previous surrogate endpoints of PCa aggressiveness, confirming that MRI grades the aggressiveness of PCa. We sought to find further evidence showing the increase in PCa aggressiveness as PI-RADS score increases from four surrogates of PCa aggressiveness: i. prostate biopsy GG (≤3 vs. >3), ii. type of pathology in surgical specimens (favourable vs. unfavourable), iii. clinical stage (localised vs. advanced), and risk of recurrence of localised PCa after primary treatment (low-intermediate vs. high). A group of 692 PCa patients were diagnosed after 3-T multiparametric MRI (mpMRI) and guided and/or systematic biopsies, showing csPCa (GG ≥ 2) in 547 patients (79%) and insignificant PCa (iPCa) in 145 (21%). The csPCa rate increased from 32.4% in PI-RADS < 3 to 95.5% in PI-RADS 5 (p < 0.001). GG ≥ 3 was observed in 7.6% of PCa with PI-RADS < 3 and 32.6% in those with PI-RADS > 3 (p < 0.001). Unfavourable pathology was observed in 38.9% of PCa with PI-RAD < 3 and 68.3% in those with PI-RADS > 3 (p = 0.030). Advanced disease was not observed in PCa with PI-RADS ≤ 3, while it existed in 12.7% of those with PI-RADS > 3 (p < 0.001). High-risk recurrence localised PCa was observed in 9.5% of PCa with PI-RADS < 3 and 35% in those with PI-RADS > 3 (p = 0.001). The PI-RADS score was an independent predictor of all surrogates of PCa aggressivene

Published
2022

20. The Barcelona Predictive Model of Clinically Significant Prostate Cancer

Author

Morote Robles, Juan, Borque-Fernando, Angel, Triquell, Marina, Celma, Ana, Regis, Lucas, Escobar, Manel, Mast, Richard, de Torres, Inés, Semidey, María E., Abascal, Jose Maria, Solà Belda, Carles, Servian, Pol, Salvador, Daniel, Santamaría, Anna, Planas, Jacques, Esteban, Luis M., Trilla Herrera, Enrique, Morote Robles, Juan, Borque-Fernando, Angel, Triquell, Marina, Celma, Ana, Regis, Lucas, Escobar, Manel, Mast, Richard, de Torres, Inés, Semidey, María E., Abascal, Jose Maria, Solà Belda, Carles, Servian, Pol, Salvador, Daniel, Santamaría, Anna, Planas, Jacques, Esteban, Luis M., and Trilla Herrera, Enrique

Abstract

Magnetic-resonance-imaging-based predictive models (MRI-PMs) improve the MRI prediction of clinically significant prostate cancer (csPCa) in prostate biopsies. Risk calculators (RC) provide easy individual assessment of csPCa likelihood. MRI-PMs have been analysed in overall populations of men suspected to have PCa, but they have never been analysed according to the prostate imaging-report and data system (PI-RADS) categories. Therefore, the true clinical usefulness of MRI-PMs regarding the specific PI-RADS categories is unknown. A new and externally validated MRI-PM for csPCa was developed in the metropolitan area of Barcelona, and a web-RC designed with the new option of selecting the csPCa probability threshold. The development cohort comprised 1486 men scheduled to undergo a 3-tesla multiparametric MRI (mpMRI) and guided and/or systematic biopsies in one academic institution of Barcelona. The external validation cohort comprised 946 men in whom the same diagnostic approach was carried out as in the development cohort, in two other academic institutions of the same metropolitan area. CsPCa was detected in 36.9% of men in the development cohort and 40.8% in the external validation cohort (p = 0.054). The area under the curve of mpMRI increased from 0.842 to 0.897 in the developed MRI-PM (p < 0.001), and from 0.743 to 0.858 in the external validation cohort (p < 0.001). A selected 15% threshold avoided 40.1% of prostate biopsies and missed 5.4% of the 36.9% csPCa detected in the development cohort. In men with PI-RADS <3, 4.3% would be biopsied and 32.3% of all existing 4.2% of csPCa would be detected. In men with PI-RADS 3, 62% of prostate biopsies would be avoided and 28% of all existing 12.4% of csPCa would be undetected. In men with PI-RADS 4, 4% of prostate biopsies would be avoided and 0.6% of all existing 43.1% of csPCa would be undetected. In men with PI-RADS 5, 0.6% of prostate biopsies would be avoided and none of the existing 42.0% of csPCa would be unde

Published
2022

25. Mapping the Patient-Oriented Prostate Utility Scale From the Expanded Prostate Cancer Index Composite and the Short-Form Health Surveys

Author

Zamora, Víctor, primary, Garin, Olatz, additional, Pardo, Yolanda, additional, Pont, Àngels, additional, Gutiérrez, Cristina, additional, Cabrera, Patricia, additional, Gómez-Veiga, Francisco, additional, Pijoan, José Ignacio, additional, Litwin, Mark S., additional, Ferrer, Montse, additional, Zamora, Víctor, additional, Ventura, Montse, additional, Guedea, Ferran, additional, Ferrer, Ferran, additional, Boladeras, Ana, additional, Slocker, Andrea, additional, Suárez, José Francisco, additional, Castells, Manuel, additional, Bonet, Xavier, additional, Delgado, David B., additional, Ortiz, MaJosé, additional, Herruzo, Ismael, additional, López-Torrecilla, José, additional, Pastor, Jorge, additional, Muñoz, Víctor, additional, Willsich, Patricia, additional, Vázquez, Marisa, additional, Roselló, Àlvar, additional, Eraso, Arantxa, additional, Ferrer, Carlos, additional, Sánchez, Ángel, additional, Macías, Víctor, additional, Fumadó, Lluís, additional, Jové, Josep, additional, Mira, Moisés, additional, Villafranca, Elena, additional, Morote, Juan, additional, Celma, Ana, additional, Samper, Pilar, additional, Glaría, Luís A., additional, Cabeza, MaÁngeles, additional, Juan, Germán, additional, Méndez Ramírez, Samuel, additional, Palacios, Amalia, additional, Béjar, Amelia, additional, Garcia, Sonia, additional, and Sabater, Sebastà, additional

Published
2021
Full Text
View/download PDF

31. MP60-20 DETECTION OF LYMPH NODE METASTASES USING POOLING METHOD BY ONE-STEP NUCLEIC ACID AMPLIFICATION (OSNA) ASSAY IN PROSTATE CANCER PATIENTS: PRELIMINARY RESULTS FROM A PROSPECTIVE-MULTICENTRE STUDY

Author

Cuadras, Mercè, primary, Regis, Lucas, additional, Planas, Jacques, additional, Celma, Ana, additional, Semidey, Ma Eugenia, additional, de Torres, Ines, additional, Ramon y Cajal, Santiago, additional, Congregado, Belén, additional, Baena, Cristina, additional, Japón, Miguel Ángel, additional, de Álava, Enrique, additional, Marcilla, David, additional, Martínez-Piñeiro, Luis, additional, Hardisson, David, additional, González-Peramato, Pilar, additional, García, Eugenia, additional, Buisán, Oscar, additional, Areal, Joan, additional, Fernández, Pedro L., additional, Carrato, Cristina, additional, Gómez, M. Carmen, additional, Morote, Juan, additional, and Trilla, Enrique, additional

Published
2021
Full Text
View/download PDF

33. MP64-04 mpMRI FOR STAGING OF PROSTATE CANCER: A MULTICENTRIC ANALYSIS OF PREDICTIVE FACTORS TO IMPROVE IDENTIFICATION OF EXTRACAPSULAR EXTENSION BEFORE RADICAL PROSTATECTOMY

Author

Regis, Lucas, primary, Triquell, Marina, additional, Winkler, Mathias, additional, Piñero, Adrià, additional, López-Molina, Cintia, additional, Valdés, Nicolás, additional, Cuadras, Mercè, additional, Celma, Ana, additional, Planas, Jacques, additional, Morote, Juan, additional, and Trilla, Enrique, additional

Published
2021
Full Text
View/download PDF

34. The Efficacy of Proclarix to Select Appropriate Candidates for Magnetic Resonance Imaging and Derived Prostate Biopsies in Men with Suspected Prostate Cancer

Author

Morote Robles, Juan, Campistol, Miriam, Celma, Ana, Regis, Lucas, de Torres, Inés, Semidey, María E., Roche, Sarai, Mast, Richard, Santamaría, Anna, Planas, Jacques, Trilla Herrera, Enrique, Morote Robles, Juan, Campistol, Miriam, Celma, Ana, Regis, Lucas, de Torres, Inés, Semidey, María E., Roche, Sarai, Mast, Richard, Santamaría, Anna, Planas, Jacques, and Trilla Herrera, Enrique

Abstract

To analyze how Proclarix is valuable to appropriately select candidates for multiparametric magnetic resonance imaging (mpMRI) and derived biopsies, among men with suspected prostate cancer (PCa). Proclarix is a new marker computing the clinically significant PCa (csPCa) risk, based on serum thosmbospondin-1, cathepsin D, prostate-specific antigen (PSA) and percent free PSA, in addition to age, that has been developed in men with serum PSA 2 to 10 ng/mL, prostate volume ≥35 mL, and normal digital rectal examination (DRE). Proclarix score (0%-100%) is analyzed in a prospective frozen serum collection of 517 correlative men scheduled for guided and/or systematic biopsies after mpMRI. Outcome variables were csPCa detection (grade group ≥2), insignificant PCa (iPCa) overdetection and avoided mpMRIs. The area under the curve of Proclarix was 0.701 (95% CI 0.637-0.765) among 281 men with serum PSA 2 to 10 ng/mL, prostate volume ≥35 mL, and -normal DRE, and 0.754 (95% CI 0.701-0.807) in the others, p=0.038. Net benefit of Proclarix existed in all men. After selecting 10% threshold, Proclarix was integrated in an algorithm which also used the serum PSA level and DRE. A reduction of 25.4% of mpMRIs request was observed and 17.7% of prostate biopsies. Overdetection of iPCa was reduced in 18.2% and 2.6% of csPCa were misdiagnosed. Proclarix is valuable in all men with suspected PCa. An algorithm integrating Proclarix score, serum PSA, and DRE can avoid mpMRI requests, unnecessary prostate biopsies and iPCa overdetection, with miniml loss of csPCa detection

Published
2021

40. MP19-01 SHOULD WE CHANGE HOW TO ASSESS EARLY CONTINENCE AFTER RHABDOSPHINCTER RECONSTRUCTION IN PATIENTS UNDERGOING ROBOTIC PROSTATECTOMY: RESULTS OF A RANDOMIZED CONTROLLED TRIAL

Author

Regis*, Lucas, primary, Salazar, Aina, additional, Planas, Jacques, additional, Celma, Ana, additional, Miret, Enric, additional, Cuadras, Merce, additional, Narvaez, Alonso, additional, Lorente, David, additional, Placer, Jose, additional, Trilla, Enrique, additional, and Morote, Juan, additional

Published
2020
Full Text
View/download PDF

41. PD63-06 MRI CONFIRMS DIFFERENT POSITION OF THE VESICOURETHRAL ANASTOMOSIS AFTER RHABDOSPHINCTER RECONSTRUCTION IN ROBOTIC PROSTATECTOMY: COHORT ANALYSES FROM A RANDOMIZED CONTROLLED TRIAL

Author

Regis*, Lucas, primary, Salazar, Aina, additional, Planas, Jacques, additional, Celma, Ana, additional, Roche, Sarai, additional, Mast, Richard, additional, Lorente, David, additional, Placer, Jose, additional, Cuadras, Merce, additional, Miret, Enric, additional, Narvaez, Mario Alonso, additional, Trilla, Enrique, additional, and Morote, Juan, additional

Published
2020
Full Text
View/download PDF

45. Accuracy of serum luteinizing hormone and serum testosterone measurements to assess the efficacy of medical castration in prostate cancer patients

Author

Morote Robles, Juan, Comas Reixach, Imma, Ferrer Costa, Roser, Planas, Jacques, Celma, Ana, Regis, Lucas, and Universitat Autònoma de Barcelona

Subjects
Male, Agonist, Luteinizing hormone, medicine.medical_specialty, medicine.drug_class, Endocrinology, Diabetes and Metabolism, Clinical Biochemistry, 030232 urology & nephrology, lcsh:Medicine, Androgen deprivation therapy, LH-RH agonist, Gonadotropin-Releasing Hormone, 03 medical and health sciences, Prostate cancer, chemistry.chemical_compound, 0302 clinical medicine, Castration Resistance, Tandem Mass Spectrometry, Internal medicine, medicine, Humans, Pharmacology (medical), Testosterone, Prospective Studies, Molecular Biology, Aged, business.industry, Research, lcsh:R, Biochemistry (medical), Area under the curve, Prostatic Neoplasms, Cell Biology, General Medicine, medicine.disease, Endocrinology, Castration, chemistry, 030220 oncology & carcinogenesis, business, Orchiectomy, Chromatography, Liquid
Abstract

Background Luteinizing hormone-releasing hormone (LH-RH) agonists are the standard for androgen deprivation therapy (ADT) in prostate cancer (PCa) patients. Current guidelines recommend serum testosterone measurement to assess the efficacy of ADT and to define castration resistance. However, serum testosterone does not reflect the exclusive effect of castration due to its extratesticular production. The aim of this study is to analyze if serum LH reflects better than serum testosterone the activity of LH-RH agonists. Methods Serum LH and serum testosterone were measured with chemiluminescent immunoassay (CLIA) in a cohort study of 1091 participants: 488 PCa patients “on LH-RH agonists”, 303 “off LH-RH agonist” in whom LH-RH agonists were withdrawn, and 350 men with PCa suspicion “no LH-RH agonist” who never received LH-RH agonists. In a validation cohort of 147 PCa patients, 124 on “LH-RH agonists” and 19 “off LH-RH agonists”, serum testosterone was also measured with liquid chromatography and tandem mass spectrometry (LC MSMS). Results The area under the curve (AUC) to distinguish patients “on versus off LH-RH agonists” was 0.997 for serum LH and 0.740 for serum testosterone, P

Published
2017

46. PD14-04 CHEMILUMINISCENT IMMUNOASSAYS SHOULD NOT BE USED TO MEASURE SERUM TESTOSTERONE IN PROSTATE CANCER PATIENTS UNDERGOING ANDROGEN DEPRIVATION THERAPY

Author

Cuadras, Mercé, primary, Miret, Enric, additional, López, Ricardo, additional, Comas, Imma, additional, Ferrer, Roser, additional, Planas, Jacques, additional, Celma, Ana, additional, Maldonado, Xavier, additional, Carles, Joan, additional, Regis, Lucas, additional, and Morote, Juan, additional

Published
2018
Full Text
View/download PDF

47. MP05-04 ANATOMICAL BENCHMARKS IN PREOPERATIVE MAGNETIC RESONANCE IMAGING PREDICT EARLY CONTINENCE RECOVERY FOLLOWING ROBOTIC RADICAL PROSTATECTOMY

Author

Regis, Lucas, primary, Cuadras, Merce, additional, Miret, Enric, additional, Lopez, Ricardo, additional, Salazar, Aina, additional, Roche, Sarai, additional, Celma, Ana, additional, Lorente, David, additional, Placer, Jose, additional, Planas, Jacques, additional, Trilla, Enrique, additional, and Morote, Juan, additional

Published
2018
Full Text
View/download PDF

48. Targeted proteomics in urinary extracellular vesicles identifies biomarkers for diagnosis and prognosis of prostate cancer

Author

Sequeiros, Tamara, primary, Rigau, Marina, additional, Chiva, Cristina, additional, Montes, Melania, additional, Garcia-Grau, Iolanda, additional, Garcia, Marta, additional, Diaz, Sherley, additional, Celma, Ana, additional, Bijnsdorp, Irene, additional, Campos, Alex, additional, Di Mauro, Primiano, additional, Borrós, Salvador, additional, Reventós, Jaume, additional, Doll, Andreas, additional, Paciucci, Rosanna, additional, Pegtel, Michiel, additional, de Torres, Inés, additional, Sabidó, Eduard, additional, Morote, Juan, additional, and Olivan, Mireia, additional

Published
2016
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results